Oragenics 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Mike Redmond

최고 경영자

US$343.8k

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	9yrs

최근 관리 업데이트

Recent updates

CEO

Mike Redmond (63 yo)

less than a year

테뉴어

US$343,800

보상

Mr. Joseph Michael Redmond, also known as Mike, serves as President of Oragenics, Inc. since December 28, 2023 and also serves as its Interim Principal Executive Officer since February 12, 2024 and served...

리더십 팀

이름	위치	테뉴어	보상	소유권
Charles Pope	Executive Chairman	14.4yrs	US$196.75k	0.23% $ 7.5k
Joseph Redmond	President & Interim Principal Executive Officer	less than a year	US$343.80k	데이터 없음
Janet Huffman	CFO, Secretary & Treasurer	1.7yrs	US$365.40k	0.13% $ 4.4k
James Kelly	Chief Medical Officer & Member of Scientific Advisor	less than a year	데이터 없음	데이터 없음
William Peacock	Chief Clinical Officer	less than a year	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 관리: OGEN 의 관리팀은 경험 (평균 재직 기간 0.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Charles Pope	Executive Chairman	14.4yrs	US$196.75k	0.23% $ 7.5k
James Kelly	Chief Medical Officer & Member of Scientific Advisor	less than a year	데이터 없음	데이터 없음
John Gandolfo	Independent Director	1.1yrs	US$25.13k	0% $ 0
Frederick Telling	Independent Director	14.4yrs	US$156.75k	0.34% $ 11.3k
Alan Dunton	Independent Director	13.6yrs	US$140.50k	0.23% $ 7.5k
Bruce Cassidy	Independent Director	1.1yrs	US$25.13k	3.15% $ 104.1k
Robert Koski	Independent Director	15.4yrs	US$134.25k	0.25% $ 8.2k
Kimberly Murphy	Director	4.5yrs	US$592.15k	0.22% $ 7.3k
Timothy Cooke	Member of Scientific Advisor	no data	데이터 없음	데이터 없음
David Zarley	Member of Scientific Advisor	no data	데이터 없음	데이터 없음
Terrence Cochrane	Member of Scientific Advisor	no data	데이터 없음	데이터 없음

9.0yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: OGEN 의 이사회는 경험(평균 재직 기간 9 년)으로 간주됩니다.

Oragenics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Insufficient new directors

Recent updates

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Oragenics, Inc. Plans to Initiate Phase II Clinical Trials

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

New major risk - Financial position

First half 2024 earnings released: US$1.21 loss per share (vs US$2.92 loss in 1H 2023)

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients

Oragenics, Inc. has completed a Follow-on Equity Offering.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics Announces NYSE American Acceptance of Plan of Compliance

Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial

First quarter 2024 earnings released: US$0.70 loss per share (vs US$1.41 loss in 1Q 2023)

Full year 2023 earnings released: US$9.18 loss per share (vs US$7.11 loss in FY 2022)

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $2.1 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion

New major risk - Share price stability

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Third quarter 2023 earnings released: US$0.85 loss per share (vs US$1.99 loss in 3Q 2022)

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.85 loss in 2Q 2022)

Oragenics, Inc. announced that it has received $0.85 million in funding

Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate

Insufficient new directors

Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. Reports Favorable Toxicology Results for Its Covid-19 Intranasal Vaccine Candidate

Oragenics, Inc. Receives NYSE American Notice Regarding Compliance with Section 1003(f)(v)

Oragenics, Inc. Announces Board Changes

Oragenics, Inc. Appoints Kimberly Murphy as Secretary and Treasurer

Oragenics, Inc. Announces Resignation of Michael Sullivan as Chief Financial Officer, Effective from December 14, 2022

Price target increased to US$2.25

Oragenics, Inc., Annual General Meeting, Dec 16, 2022

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Price target increased to US$2.25

Oragenics, Inc. Appoints Kimberly M. Murphy as Chief Executive Officer

Oragenics Announces Publication of Positive Data for Its NT-Cov2-1 Intranasal Covid-19 Vaccine Candidate in Scientific Reports

Price target decreased to US$2.25

Executive Chairman recently bought US$66k worth of stock

Price target decreased to US$2.25

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

Oragenics, Inc. Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations SARS-CoV-2 Vaccine Candidate

Price target increased to US$2.25

Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령